Researchers from the University of Illinois at Chicago and Harvard University have published details on the chemical synthesis and microbiological evaluation of a ribosome-binding antibiotic – cresomycin (CRM) – that was able to overcome antimicrobial resistance of major pathogenic bacteria including Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa and others.